Base de dados : HANSEN Pesquisa : CLOFAZIMINA/EF ADV [Descritor de assunto] Referências encontradas : 12 [refinar] Mostrando: 1 .. 12   no formato [Detalhado]

página 1 de 1

1 / 12

HANSEN

seleciona para imprimir

Id: 20765 Autor: Kaluarachchi, S. I; Fernandopulle, B. M. R; Gunawardane, B. P Título: Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study ..- Fonte: s.l; s.n; 2001. 9 p. tab. Resumo: This study analyses retrospectively some of the risks associated with the use of WHO-multidrug therapy (MDT) in Sri Lanka. Case records of 3,333 new cases of leprosy attending the Central Leprosy Clinic in Colombo during 1991-1995, were analysed for adverse drug reactions involving the liver and blood. There were 81 reports of suspected hepatic or haematological adverse reactions associated with the use of MDT, of which 39 were classified as haemolytic anaemia, 25 as toxic hepatitis, 2 as methaemoglobinaemia and 15 as anaemia. Dapsone, was incriminated in the majority of adverse reactions (72 per cent). Adverse drug reactions were more common in female than male subjects (55 per cent vs 45 per cent; P < 0.5), but there was no significant differences between the age groups. Majority of adverse reactions was seen within the first three months of initiation of MDT. This study in no way undermines the benefits of MDT but highlights the risks and suggests measures to minimize these risks. (AU). Descritores: ANEMIA/ind quim ANEMIA/epidemiol CLOFAZIMINA/ef adv DAPSONA/ef adv QUIMIOTERAPIA COMBINADA HEPATITE TOXICA/epidemiol HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/quimioter ESTUDOS RETROSPECTIVOS RIFAMPINA/ef adv RIFAMPINA/uso terap METEMOGLOBINEMIA/ind quim METEMOGLOBINEMIA/epidemiol Limites: HUMANO MASCULINO FEMININO CRIANÇA ADULTO MEIA-IDADE ADOLESCENTE Meio Eletrônico: - . Localização: BR191.1; 09163/s

2 / 12

HANSEN

seleciona para imprimir

Id: 18503 Autor: Kaluarachchi, S. I; Fernandopulle, B. M. R; Gunawardane, B. P Título: Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study ..- Fonte: s.l; s.n; 2001. 9 p. tab. Resumo: This study analyses retrospectively some of the risks associated with the use of WHO-multidrug therapy (MDT) in Sri Lanka. Case records of 3,333 new cases of leprosy attending the Central Leprosy Clinic in Colombo during 1991-1995, were analysed for adverse drug reactions involving the liver and blood. There were 81 reports of suspected hepatic or haematological adverse reactions associated with the use of MDT, of which 39 were classified as haemolytic anaemia, 25 as toxic hepatitis, 2 as methaemoglobinaemia and 15 as anaemia. Dapsone, was incriminated in the majority of adverse reactions (72 per cent). Adverse drug reactions were more common in female than male subjects (55 per cent vs 45 per cent; P < 0.5), but there was no significant differences between the age groups. Majority of adverse reactions was seen within the first three months of initiation of MDT. This study in no way undermines the benefits of MDT but highlights the risks and suggests measures to minimize these risks. (AU). Descritores: ANEMIA/ind quim ANEMIA/epidemiol CLOFAZIMINA/ef adv DAPSONA/ef adv QUIMIOTERAPIA COMBINADA HEPATITE TOXICA/epidemiol HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/quimioter METEMOGLOBINEMIA/ind quim METEMOGLOBINEMIA/epidemiol ESTUDOS RETROSPECTIVOS RIFAMPINA/ef adv RIFAMPINA/uso terap Limites: HUMANO MASCULINO FEMININO CRIANÇA ADULTO ADOLESCENTE Meio Eletrônico: - . Localização: BR191.1; 09123/s

3 / 12

HANSEN

seleciona para imprimir

Id: 18489 Autor: Goulart, Isabela Maria Bernades; Arbex, Guilherme Leonel; Carneiro, Marcus Hubaide; Rodrigues, Mariana Scalia; Gadia, Rafael Título: Efeitos adversos da poliquimioterapia em pacientes com hanseníase: um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia- Fonte: s.l; s.n; set.-out. 2002. 8 p. tab. Resumo: The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlandia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7 per cent) were related to dapsone, 7 (6.2 per cent) were caused by rifampicin and 26 (20.5 per cent) were attributed to clofazimine. These effects induced 28 (14.9 per cent), patients to change the therapeutic scheme, representing 39.4 per cent from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem. (AU). Descritores: CLOFAZIMINA/admin CLOFAZIMINA/ef adv DAPSONA/admin DAPSONA/ef adv QUIMIOTERAPIA COMBINADA HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENIASE/quimioter COOPERACAO DO PACIENTE/estatíst DESISTÊNCIA DO PACIENTE/estatíst ESTUDOS RETROSPECTIVOS RIFAMPINA/admin RIFAMPINA/ef adv Limites: PRÉ-ESCOLAR CRIANÇA ADOLESCENCIA ADULTO RESUMO EM INGLES FEMININO HUMANO LACTENTE RECEM-NASCIDO MASCULINO MEIA-IDADE Localização: BR191.1; 09017/s

4 / 12

HANSEN

seleciona para imprimir

Id: 18476 Autor: Queiroz, Regina Helena Costa; Souza, Ana Maria de; Sampaio, Suely Vilela; Melchior Junior, Enzo Título: Biochemical and hematological side effects of clofazimine in leprosy patients ..- Fonte: s.l; s.n; 2002. 4 p. tab. Resumo: Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ). Hematological and biochemical alterations have been cited among other side effects; however, their real magnitude and clinical significance at the doses currently employed in therapy have not been sufficiently documented. We therefore investigated the correlation between CFZ plasma concentration and biochemical (transaminases, bilirubins, alkaline phosphatase, gamma-glutamyltransferase, amylase, urea, creatinine, and potassium plasma levels) as well as hematological changes blood and reticulocyte counts, osmotic fragility, detection of Heinz bodies and methemoglobinemia (MHM), following in two regimes of treatment: CFZ as a single drug and CFZ as part of multidrug (MDT) therapy, in combination with dapsone and rifampicin. MHM and hemolytic anemia were detected in the MDT group only. Eosinophilia was found in patients of either group. Determination of hepatic, pancreatic and renal biochemical parameters showed rare, occasional changes of apparently no clinical significance. We conclude that CFZ is a generally well tolerated and safe drug when given as a daily dose of 50mg, which is currently used in leprosy patients. (AU). Descritores: CONTAGEM DE CELULAS SANGUINEAS CLOFAZIMINA/admin CLOFAZIMINA/ef adv CLOFAZIMINA/uso terap DAPSONA/admin DAPSONA/ef adv DAPSONA/uso terap QUIMIOTERAPIA COMBINADA HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/sangue HANSENIASE/quimioter RIFAMPINA/admin RIFAMPINA/ef adv RIFAMPINA/uso terap Limites: SUPPORT, NON-U.S. GOV'T FEMININO HUMANO MASCULINO Meio Eletrônico: - . Localização: BR191.1; 08998/s

5 / 12

HANSEN

seleciona para imprimir

Id: 18456 Autor: Yawalkar, S. J; Vischer, W Título: Lamprene (clofazimine) in leprosy ..- Fonte: s.l; s.n; jun. 1979. 10 p. graf. Resumo: We are extremely grateful to CIBA-GEIGY Limited for permission to reproduce in full this 15-page booklet on a drug of increasing interest and value in the treatment of leprosy.(AU). Descritores: CLOFAZIMINA/ef adv CLOFAZIMINA/metab CLOFAZIMINA/uso terap HANSENIASE/quimioter - QUIMICA Limites: HUMANO Meio Eletrônico: - . Localização: BR191.1; 01138/s

6 / 12

HANSEN

seleciona para imprimir

Id: 17969 Autor: Lal, Sardari; Garg, B. R; Hameedulla, A Título: Gastro-intestinal side effects of clofazimine ..- Fonte: s.l; s.n; apr. 1981. 4 p. . Resumo: Three out of 30 patients of leprosy getting clofazimine therapy developed severe gastrointestinal side effects following the therapy in the dose of 100 mg after one month, eight months and five weeks respectively. One of the patients died due to the side effects. Indian patients appear to be more prone to severe gastrointestinal side effects of clofazimine and may develop the same after shorter duration of therapy with smaller doses of the drug.(AU). Descritores: GASTROENTEROPATIAS/ind quim CLOFAZIMINA/ef adv HANSENIASE/quimioter Limites: RELATO DE CASO HUMANO MASCULINO FEMININO ADULTO Meio Eletrônico: - . Localização: BR191.1; 00772/s

7 / 12

HANSEN

seleciona para imprimir

Id: 14984 Autor: Naafs, Ben Título: Viewpoint: Leprosy after the year 2000 ..- Fonte: s.l; s.n; 2000. 4 p. . Descritores: HANSENIASE HANSENIASE HANSENIASE LEPROSTATICOS PELE CLOFAZIMINA QUIMIOTERAPIA COMBINADA HIPERSENSIBILIDADE TARDIA PREVALENCIA SAUDE PUBLICA RIFAMPINA Localização: BR191.1; 07425/s

8 / 12

HANSEN

seleciona para imprimir

Id: 14197 Autor: Queiroz, Regina Helena Costa; Melchior Junior, Enzo; Souza, Ana Maria de; Gouveia, Elias; Barbosa, Jose Carlos; Carvalho, Dermeval de Título: Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT ..- Fonte: s.l; s.n; 1997. 5 p. tab. Descritores: HANSENIASE HANSENIASE CLOFAZIMINA CLOFAZIMINA DAPSONA DAPSONA QUIMIOTERAPIA COMBINADA LEPROSTATICOS METEMOGLOBINEMIA RIFAMPINA RIFAMPINA Localização: BR191.1; 07131/s

9 / 12

HANSEN

seleciona para imprimir

Id: 13978 Autor: Chong, Pek-Yoon; Ti, Thiow-Kong Título: Severe abdominal pain in low doseage clofazimine ..- Fonte: s.l; s.n; 1993. 3 p. ilus. Descritores: DOR ABDOMINAL DOR ABDOMINAL DOR ABDOMINAL CLOFAZIMINA HANSENIASE GANGLIOS LINFATICOS Localização: BR191.1; 06624/s

10 / 12

HANSEN

seleciona para imprimir

Id: 13355 Autor: Reeve, P. A; Ala, J; Hall, J. J Título: Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy ..- Fonte: s.l; s.n; 1992. 5 p. tab. Descritores: ADOLESCENCIA CLOFAZIMINA DAPSONA DAPSONA ERUPÇAO POR DROGA QUIMIOTERAPIA QUIMIOTERAPIA COMBINADA HEPATITE TOXICA INCIDENCIA HANSENIASE RIFAMPINA SINDROME VANUATU Localização: BR191.1; 06433/s

11 / 12

HANSEN

seleciona para imprimir

Id: 13172 Autor: Mendes, Abraao Garcia; Campos, Wesley Ribeiro; Orefice, Fernando; Monteiro, Lilian Grace; Sucena, Maria Aparecida Título: Impregnacao sui generis conjuntivo escleral por clofazimina em um paciente portador de hanseniase Impregnation sui generis of the conjunctiva and sclera by clofazimine in a carrier Hansen's disease- Fonte: s.l; s.n; 1994. 8 p. ilus. Descritores: CONJUNTIVA ESCLERA HANSENIASE CLOFAZIMINA CLOFAZIMINA Localização: BR191.1; 06173/s

12 / 12

HANSEN

seleciona para imprimir

Id: 13133 Autor: Neves, Rene Garrido Título: Terapeutica da hanseniase: situacao atual ?- Fonte: s.l; s.n; abr. 1992. 23 p. tab. Descritores: HANSENIASE HANSENIASE SULFONAS SULFONAS SULFONAS RIFAMPINA RIFAMPINA RIFAMPINA CLOFAZIMINA CLOFAZIMINA CLOFAZIMINA TIOAMIDAS TIOAMIDAS TIOAMIDAS Localização: BR191.1; 06138/s

---

página 1 de 1

Refinar a pesquisa

Base de dados : HANSEN

Formulário avançado

Pesquisar por : Formulário livre

		Pesquisar	no campo
1			PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro
2	and or and not		PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro
3	and or and not		PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro

Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information